摘要
目的探讨125I放射性粒子联合动脉灌注化疗治疗胰腺癌的临床疗效,评价双介入治疗的应用价值。方法 38例中晚期胰腺癌患者先行CT下125I放射性粒子植入术,术后7天行腹腔动脉灌注化疗术,术后随访观察肿瘤变化、临床受益率、生存期等。结果 38例患者均手术成功,术后1个月临床受益率为92.1%,有效率71%,术后6、12、24个月生存率分别为97.4%、57.9%、21.1%。结论 125I放射性粒子联合动脉灌注化疗治疗胰腺癌可明显减轻患者疼痛症状,临床受益率高,并发症少,术后生存率长,值得临床应用推广。
Objective To evaluate the efficacy of iodine-125 seeds implantation combined with arterial infusion chemotherapy in treating patients with pancreatic cancer. Methods Thirty-eight patients with nonresectable pancreatic cancer received implantation of iodine-125 seeds under CT guidance firstly; then received arterial infusion chemotherapy seven days after the implantation. Tumor response rate, clinical benefit response and survival rates were observed. Results All the operations were succeed, the clinical benefit response （CBR） was 92.1%, the tumor response rate was 71%, the survival rates of 6-month,12-month, 24-month were 97.4%, 57.9%, 21.1% respectively. Conclusion The combination iodine-125 seeds implantation and arterial infusion chemotherapy in treating patients with pancreatic cancer has high clinical benefit response, tumor response rate and also significantly relief pain. Its treatment value is worth clinical popularizing and application.
出处
《当代医学》
2012年第27期71-74,共4页
Contemporary Medicine
